Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
Company profile
Ticker
CERS
Exchange
Website
CEO
William Greenman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Cerus Europe B.V. ...
IRS number
680262011
CERS stock data
Latest filings (excl ownership)
SD
Conflict minerals disclosure
31 May 23
DEFA14A
Additional proxy soliciting materials
23 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Cerus Corporation Announces First Quarter 2023 Financial Results
4 May 23
EFFECT
Notice of effectiveness
4 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Entry into a Material Definitive Agreement
5 Apr 23
8-K
Other Events
10 Mar 23
Transcripts
CERS
Earnings call transcript
2023 Q1
4 May 23
CERS
Earnings call transcript
2022 Q4
28 Feb 23
CERS
Earnings call transcript
2022 Q3
3 Nov 22
CERS
Earnings call transcript
2022 Q2
4 Aug 22
CERS
Earnings call transcript
2022 Q1
6 May 22
CERS
Earnings call transcript
2021 Q4
23 Feb 22
CERS
Earnings call transcript
2021 Q3
3 Nov 21
CERS
Earnings call transcript
2021 Q2
4 Aug 21
CERS
Earnings call transcript
2021 Q1
5 May 21
CERS
Earnings call transcript
2020 Q4
26 Feb 21
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 29.39 mm | 29.39 mm | 29.39 mm | 29.39 mm | 29.39 mm | 29.39 mm |
| Cash burn (monthly) | 2.66 mm | 915.50 k | 5.19 mm | 3.81 mm | 2.83 mm | 1.05 mm |
| Cash used (since last report) | 6.16 mm | 2.12 mm | 12.03 mm | 8.83 mm | 6.57 mm | 2.45 mm |
| Cash remaining | 23.23 mm | 27.27 mm | 17.36 mm | 20.56 mm | 22.82 mm | 26.94 mm |
| Runway (months of cash) | 8.7 | 29.8 | 3.3 | 5.4 | 8.1 | 25.5 |
Institutional ownership, Q1 2023
82.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 161 |
| Opened positions | 11 |
| Closed positions | 37 |
| Increased positions | 60 |
| Reduced positions | 50 |
| 13F shares | Current |
|---|---|
| Total value | 438.15 bn |
| Total shares | 149.61 mm |
| Total puts | 90.80 k |
| Total calls | 138.50 k |
| Total put/call ratio | 0.7 |
| Largest owners | Shares | Value |
|---|---|---|
| ARK Investment Management | 22.10 mm | $65.64 bn |
| Baker Bros. Advisors | 16.07 mm | $47.72 bn |
| BLK Blackrock | 13.01 mm | $38.63 bn |
| Vanguard | 10.54 mm | $31.31 bn |
| Primecap Management | 8.82 mm | $26.18 bn |
| CMTDF Sumitomo Mitsui Trust | 8.02 mm | $23.81 bn |
| Nikko Asset Management Americas | 8.02 mm | $22.45 bn |
| Senvest Management | 5.56 mm | $16.50 bn |
| Wasatch Advisors | 5.02 mm | $14.90 bn |
| STT State Street | 4.81 mm | $14.29 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 Jun 23 | Eric Bjerkholt | Common Stock | Grant | Acquire A | No | No | 5 | 40,000 | 200.00 k | 122,133 |
| 7 Jun 23 | Ann Lucena | Common Stock | Grant | Acquire A | No | No | 5 | 40,000 | 200.00 k | 64,784 |
| 7 Jun 23 | Moore Timothy L. | Common Stock | Grant | Acquire A | No | No | 5 | 40,000 | 200.00 k | 105,073 |
| 7 Jun 23 | Jami K Nachtsheim | Common Stock | Grant | Acquire A | No | No | 5 | 40,000 | 200.00 k | 106,362 |
| 7 Jun 23 | Schulze Gail | Common Stock | Grant | Acquire A | No | No | 5 | 40,000 | 200.00 k | 123,420 |
Press releases
Thinking about buying stock in Vera Bradley, Yext, Chindata, Cerus, or Avrobio?
7 Jun 23
Cerus Corporation Announces Follow-on Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate
5 Jun 23
Cerus Corporation Announces First Quarter 2023 Financial Results
4 May 23
Cerus Corporation to Release First Quarter 2023 Financial Results on May 4, 2023
20 Apr 23